HTG Molecular Diagnostics, Firalis Partner on NGS-Based RA Theranostic | GenomeWeb

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and French biotechnology firm Firalis announced yesterday that they have formed a partnership to develop a next-generation sequencing-based assay for identifying rheumatoid arthritis (RA) patients like to respond to anti-TNF-alpha therapies.

Called RABIOPRED, the assay was developed through a EU-funded project led by French personalized medicine firm Tc Land Expression and Firalis. It is based on a gene-expression panel that includes more than 2,100 microRNAs and runs on HTG's EdgeSeq platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy. 

Dec
13
Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Dec
15
Sponsored by
PierianDx

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.